Navigation Links
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Date:3/12/2009

exposed to a very potent stimulant (TRAP-thrombin receptor agonist peptide)," said Enrico Veltri, M.D., group vice president of global clinical research, cardiovascular and metabolic disease, Schering-Plough Research Institute. "These data, along with subsequent data from Phase II acute coronary syndromes (ACS) and stroke studies conducted in Japan, suggest that TRA is a novel medication that targets a pathway to platelet aggregation not addressed by existing medications."

The 1,030-patient TRA-PCI trial was designed to evaluate the safety and tolerability of TRA in patients undergoing PCI. A secondary objective was to assess whether patients treated with the compound in addition to standard-of-care therapies had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared to patients treated with the standard of care alone. While not powered to establish efficacy, the study did report a non-statistically significant 46 percent reduction in cardiovascular events at the highest TRA dose tested compared to standard of care alone. Preliminary results were presented in March 2007 at the American College of Cardiology/i2 Summit in New Orleans by David J. Moliterno, M.D., Chief of Cardiovascular Medicine, University of Kentucky College of Medicine, and Medical Director of the Linda and Jack Gill Heart Institute, on behalf of the TRA-PCI investigators.

Study Design

The Phase II TRA-PCI trial was a multinational, randomized, double-blind, placebo-controlled dose-ranging trial assessing both oral loading doses as well as maintenance doses of Schering-Plough's TRA. The trial enrolled 1,030 patients 45 years or older, with coronary artery disease for whom PCI was planned, and randomized to one of three oral loading doses of TRA (10mg, 20mg or 40mg) or placebo in a 3:1 ratio of active drug to placebo. The loading doses were increased in a sequential fas
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
(Date:7/11/2014)...  Kindred Hospital Houston Northwest, with Wound Care ... its new outpatient wound healing center.  The wound ... chronic, hard to heal wounds. Chronic wounds include ... lower leg wounds related to blood flow issues, ... injury wounds which are complex and demonstrate delayed ...
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
Breaking Medicine Technology:New Technologies Transforming Consumer Marketing Research Playbook 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Veran Medical Publishes Lung Cancer Patient Management Study 2
... WASHINGTON, Nov. 2, 2011 The Long Term Care ... by the Centers for Medicare and Medicaid Services (CMS) ... as a consideration of the Conditions of Participation for ... Our member companies and individual pharmacists have ...
... AMSTERDAM, November 2, 2011 Elsevier, ... information products and services, announced today that its ... purchase on SciVerse ScienceDirect, Elsevier,s online platform for ... in the breadth and depth of the eBook ...
Cached Medicine Technology:Proposed CMS Changes Related to Consultant Pharmacists Raise Profound Concerns for Pharmacies 2Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 2Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 3
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Reducing the number ... incidence of Lyme disease and other tick-borne infections among ... deer populations can be manipulated to reduce human interactions ... contracting Lyme disease," the researchers wrote. White-tailed deer ... transmit Lyme disease to people. The study included ...
(Date:7/11/2014)... 11, 2014 Volunteers from Scientology ... abuse this week with drug education lectures, forums and ... distribution in cities around the world. , Drug abuse ... Institute on Drug Abuse, abuse of alcohol and illicit ... crime, lost work, decreased productivity and healthcare. , ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... by Types, Applications & Geography - 2018,” defines ... fiber market with an analysis and forecast of ... specialty synthetic fibers (Para aramids, meta aramids, UHMW ... others including PPS fiber, PBI fiber, PBO fiber, ...
(Date:7/11/2014)... 11, 2014 Utilizing the Keller Funnel, ... William Koenig, has topped a record number of complication-free ... performed over 400 successful procedures without the occurrence of ... well known across the country for his expertise with ... has long been the foundation for numerous studies and ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2
... ... ... ... ...
... , ... ... ... ...
... ... ... , ... , , ...
... ... ... , , ... WASHINGTON , ...
... type of blood cancer, mixed lineage leukemia (MLL), has an ... cells rely on the normal version of an associated protein ... of chromosome 11 breaks off at the normal MLL-associated gene. ... a fusion protein that eventually causes uncontrolled growth of blood ...
... ... Health Systems. The Meaningful Use Dashboard will provide a single location where an organization ... Indicators. , ... OH (PRWEB) February 26, 2010 -- Health Care DataWorks , a Technology Company ...
Cached Medicine News:Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 2Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 3Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 4Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 5Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 6Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 7Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 8Health News:CPR Instruction Via Cell Phone Effective 2Health News:CPR Instruction Via Cell Phone Effective 3Health News:CPR Instruction Via Cell Phone Effective 4Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 2Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 3Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 4Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 2Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 3Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 4Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 5Health News:Cells of aggressive leukemia hijack normal protein to grow 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: